(The following press release from Merck KGAA was received by e-mail. It 
was not confirmed by the sender.) 
News Release 
Your Contact
Andrea Marquart
+49 6151 72-6517 
Merck Serono Enters into Research Agreement with Pfizer and
Broad Institute 
• Agreement aims to identify biomarkers relevant to future therapies in the
  area of Systemic Lupus Erythematosus and Lupus Nephritis 
Darmstadt, Germany, April 1, 2014 – Merck Serono, the biopharmaceutical
division of Merck, announced today that its U.S. affiliate EMD Serono has
signed a research agreement with Pfizer Inc. and the Broad Institute in
Cambridge, Massachusetts, U.S. The collaboration is focused on the genomic
profiling of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN)
patients. The research project will be jointly funded by Merck Serono and
The complete Merck News Release can be downloaded at the following link:$File/Final_MerckSeron
News Releases from Merck KGaA, Darmstadt, Germany, are available at this
address: or for residents in the USA and Canada at 
In case you are a resident of the USA or Canada please go to to register again for your online
subscription of this service as our newly introduced geo-targeting requires
new links in the email. 
You may change your subscription at any time by following either one of the
following links: or
And please feel free to unsubscribe this service with either or
Thank you very much! 
Merck KGaA
Group Communications
External Communications
Frankfurter Str. 250
64293 Darmstadt
Mandatory Information can be found at
Hotline: +49 6151 72-5000 
This message and any attachment are confidential and may be privileged or
otherwise protected from disclosure. If you are not the intended recipient,
you must not copy this message or attachment or disclose the contents to
any other person. If you have received this transmission in error, please
notify the sender immediately and delete the message and any attachment
from your system. Merck KGaA, Darmstadt, Germany and any of its
subsidiaries do not accept liability for any omissions or errors in this
message which may arise as a result of E-Mail-transmission or for damages
resulting from any unauthorized changes of the content of this message and
any attachment thereto. Merck KGaA, Darmstadt, Germany and any of its
subsidiaries do not guarantee that this message is free of viruses and does
not accept liability for any damages caused by any virus transmitted
Click to access the German, French, Spanish and
Portuguese versions of this disclaimer.
Press spacebar to pause and continue. Press esc to stop.